1.
|
10 p, 1.4 MB |
Experimental study of the quantification of indocyanine green fluorescence in ischemic and non-ischemic anastomoses, using the SERGREEN software program
/
Serra-Aracil, Xavier (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
García-Nalda, Albert (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Serra-Gómez, Borja (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Serra-Gómez, Álvaro (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Mora-López, Laura (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Pallisera-Lloveras, Anna (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Lucas-Guerrero, Victoria (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Navarro-Soto, Salvador (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Universitat Autònoma de Barcelona
Tissue ischemia is a key risk factor in anastomotic leak (AL). Indocyanine green (ICG) is widely used in colorectal surgery to define the segments with the best vascularization. In an experimental model, we present a new system for quantifying ICG fluorescence intensity, the SERGREEN software. [...]
2022 - 10.1038/s41598-022-17395-6
Scientific reports, Vol. 12 (july 2022)
|
|
2.
|
14 p, 3.9 MB |
Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage colon cancer
/
Lahoz, Sara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Archilla, Ivan (Universitat de Barcelona) ;
Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Hernández-Illán, Eva (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ferrer Menduiña, Queralt (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
López-Prades, Sandra (Universitat de Barcelona) ;
Nadeu, Ferran (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Del Rey Azpiri, Javier (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Sanz-Pamplona, Rebeca (Institut d'Investigació Biomèdica de Bellvitge) ;
Lozano, Juan José (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Cuatrecasas, Miriam (Universitat de Barcelona) ;
Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Optimal selection of high-risk patients with stage II colon cancer is crucial to ensure clinical benefit of adjuvant chemotherapy. Here, we investigated the prognostic value of genomic intratumor heterogeneity and aneuploidy for disease recurrence. [...]
2022 - 10.1002/path.5870
The Journal of Pathology, Vol. 257, Num. 1 (April 2022) , p. 68-81
|
|
3.
|
8 p, 1.5 MB |
Artificial intelligence to improve polyp detection and screening time in colon capsule endoscopy
/
Gilabert, Pere (Universitat de Barcelona. Departament de Matemàtiques i Informàtica) ;
Vitrià i Marca, Jordi (Universitat de Barcelona. Departament de Matemàtiques i Informàtica) ;
Laiz, Pablo (Universitat de Barcelona. Departament de Matemàtiques i Informàtica) ;
Malagelada Prats, Carolina (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Watson, Angus (Department of Colorectal Surgery, Raigmore Hospital, NHS Highland) ;
Wenzek, Hagen (CorporateHealth International ApS (Dinamarca)) ;
Segui, Santi (Universitat de Barcelona. Departament de Matemàtiques i Informàtica)
Colon Capsule Endoscopy (CCE) is a minimally invasive procedure which is increasingly being used as an alternative to conventional colonoscopy. Videos recorded by the capsule cameras are long and require one or more experts' time to review and identify polyps or other potential intestinal problems that can lead to major health issues. [...]
2022 - 10.3389/fmed.2022.1000726
Frontiers in Medicine, Vol. 9 (october 2022)
|
|
4.
|
12 p, 1.2 MB |
Colorectal cancer health services research study protocol : the CCR-CARESS observational prospective cohort project
/
Quintana López, José María (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Gonzalez, Nerea (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Anton-Ladislao, Ane (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Redondo, Maximino (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Baré i Mañas, Marisa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Fernandez de Larrea, Nerea (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Briones, Eduardo (Salud Publica (Sevilla)) ;
Escobar, Antonio (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Sarasqueta, Cristina (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Garcia-Gutierrez, Susana (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Aguirre, Urko (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Universitat Autònoma de Barcelona
Colorectal cancers are one of the most common forms of malignancy worldwide. But two significant areas of research less studied deserve attention: health services use and development of patient stratification risk tools for these patients. [...]
2016 - 10.1186/s12885-016-2475-y
BMC Cancer, Vol. 16 (july 2016)
|
|
5.
|
20 p, 2.7 MB |
Intracellular Delivery of Anti-SMC2 Antibodies against Cancer Stem Cells
/
Montero, Sara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Andrade, Fernanda (Universidade do Porto) ;
Martinez-Trucharte, Francesc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vilar-Hernández, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Quesada, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Xandri Monje, Helena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rafael, Diana (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Schwartz, Simon (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Universitat Autònoma de Barcelona
Structural maintenance of chromosomes protein 2 (SMC2) is a central component of the condensin complex involved in DNA supercoiling, an essential process for embryonic stem cell survival. SMC2 over-expression has been related with tumorigenesis and cancer malignancy and its inhibition is regarded as a potential therapeutic strategy even though no drugs are currently available. [...]
2020 - 10.3390/pharmaceutics12020185
Pharmaceutics, Vol. 12 (february 2020)
|
|
6.
|
6 p, 754.7 KB |
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial
/
Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ;
André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ;
Taieb, Julien (UMR-S 1147, INSERM) ;
Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ;
Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Hickish, Tamas (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ;
Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ;
Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - 10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317
|
|
7.
|
14 p, 2.8 MB |
EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer
/
Roman-Canal, Berta (Universitat Autònoma de Barcelona) ;
Tarragona, Jordi (Institut de Recerca Biomèdica de Lleida) ;
Moiola, Cristian Pablo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gatius, Sònia (Institut de Recerca Biomèdica de Lleida) ;
Bonnin, Sarah (Centre de Regulació Genòmica) ;
Ruiz-Miró, Maria (Institut de Recerca Biomèdica de Lleida) ;
Sierra, José Enrique (Institut de Recerca Biomèdica) ;
Rufas, Maria (Institut de Recerca Biomèdica) ;
González, Esperanza (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Porcel, José M. (Institut de Recerca Biomèdica de Lleida) ;
Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron) ;
Falcón-Pérez, Juan M.. (IKERBASQUE, Basque Foundation for Science) ;
Ponomarenko, Julia (Universitat Pompeu Fabra) ;
Matias-Guiu, Xavier (Institut de Recerca Biomèdica de Lleida) ;
Colás Ortega, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Colorectal cancer (CRC) is the third leading cause of cancer-related mortality worldwide. Current systematic methods for diagnosing have inherent limitations so development of a minimally-invasive diagnosis, based on the identification of sensitive biomarkers in liquid biopsies could therefore facilitate screening among population at risk. [...]
2019 - 10.1186/s12967-019-1954-8
Journal of translational medicine, Vol. 17 (june 2019)
|
|
8.
|
None, 920.0 KB |
Microbiome and colorectal cancer : Roles in carcinogenesis and clinical potential
/
Saus, Ester (Universitat Pompeu Fabra) ;
Iraola-Guzmán, Susana (Universitat Pompeu Fabra) ;
Willis, Jesse R. (Universitat Pompeu Fabra) ;
Brunet Vega, Anna (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gabaldón, Toni (Institució Catalana de Recerca i Estudis Avançats)
The gastrointestinal tract harbors most of the microbiota associated with humans. In recent years, there has been a surge of interest in assessing the relationships between the gut microbiota and several gut alterations, including colorectal cancer. [...]
2019 - 10.1016/j.mam.2019.05.001
Molecular Aspects of Medicine, Vol. 69 (october 2019) , p. 93-106
|
|
9.
|
9 p, 435.9 KB |
Prediction of overall survival in stage II and III colon cancer beyond TNM system : a retrospective, pooled biomarker study
/
Dienstmann, Rodrigo. (Hospital Universitari Vall d'Hebron) ;
Mason, M. J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Sinicrope, F. A. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ;
Phipps, A. I. (Fred Hutchinson Cancer Research Center, Seattle, USA) ;
Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Nesbakken, A. (Oslo University Hospital (Oslo, Noruega)) ;
Danielsen, S. A. (Oslo University Hospital (Oslo, Noruega)) ;
Sveen, A. (Oslo University Hospital (Oslo, Noruega)) ;
Buchanan, Daniel D (The University of Melbourne) ;
Clendenning, M. (The University of Melbourne) ;
Rosty, C. (The University of Melbourne) ;
Bot, Brian M (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Alberts, S. R. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ;
Milburn Jessup, J. (National Cancer Institute (Rockville, Estats Units d'Amèrica)) ;
Lothe, R. A. (Oslo University Hospital (Oslo, Noruega)) ;
Delorenzi, Mauro (SIB Swiss Institute Bioinformatics, Lausanne, Switzerland) ;
Newcomb, P. A. (Fred Hutchinson Cancer Research Center, Seattle, USA) ;
Sargent, D. (Mayo Clinic, Rochester, USA) ;
Guinney, J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Universitat Autònoma de Barcelona
TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation. [...]
2017 - 10.1093/annonc/mdx052
Annals of oncology, Vol. 28 (february 2017) , p. 1023-1031
|
|
10.
|
22 p, 644.2 KB |
Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer
/
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Matsusaka, Satoshi (Keck School of Medicine, University of Southern California) ;
Zhang, Wu (Keck School of Medicine, University of Southern California) ;
Yang, Dongyun (Keck School of Medicine, University of Southern California) ;
Ning, Yan (Keck School of Medicine, University of Southern California) ;
Stremitzer, Stefan (Keck School of Medicine, University of Southern California) ;
Stintzing, Sebastian (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich, Munich, Germany) ;
Sunakawa, Yu (Keck School of Medicine, University of Southern California) ;
Yamauchi, Shinichi (Keck School of Medicine, University of Southern California) ;
Fujimoto, Yoshiya (Cancer Institute Hospital. Department of Gastroenterological Surgery (Tokyo)) ;
Ueno, Masashi (Cancer Institute Hospital. Department of Gastroenterological Surgery (Tokyo)) ;
Lenz, Heinz-Josef (Keck School of Medicine, University of Southern California) ;
Universitat Autònoma de Barcelona
The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil. In this study 14 polymorphisms in 8 genes involved in the Hippo pathway (MST1, MST2, LATS1, LATS2, YAP, TAZ, FAT4 and RASSF1A) were evaluated as recurrence predictors in 194 patients with stages II/III colon cancer treated with 5-Fu-based adjuvant chemotherapy. [...]
2015 - 10.1038/tpj.2015.64
The pharmacogenomics journal, Vol. 16 (september 2015) , p. 312-319
|
|